-
Biocon Biologics sees Biopharma SHAKTI as major boost for India’s biosimilar ambitions
01 Feb 2026 12:30 GMT
… .
Speaking to ET Now, Biocon Biologics CEO and MD Shreehas … Responding to questions on how Biocon Biologics plans to leverage the … what this means specifically for Biocon Biologics and the size … is over $270 billion of patented drugs that are losing exclusivity …
-
Biosimilars Market to Reach US$86.2 Bn by 2032 at 13.9% CAGR: Persistence Market Research
02 Feb 2026 16:00 GMT
… , driven by chronic disease prevalence, patent expiries, affordable therapies, and expanding … prevalence of chronic diseases, expiring patents of high-value biologics, and … Pfizer, Sandoz, Eli Lilly, Amgen, Biocon, and Celltrion, emphasize high-precision …
-
The Succeeding Patent Edge: Strategic Implications for Pharma Revenue, Portfolios and Innovation
12 Jan 2026 13:26 GMT
… Johnson will lose patent for Imbruvica, while Amgen, Mylan, Biocon, etc., are … encourage innovative formulations to extend patent protection.
Keytruda is set to … Keytruda, which encompasses approximately 300 patent applications that cover various indications …
-
Semaglutide patent expiry opens over Rs 50,000 Cr opportunity for drugmakers: Report
05 Jan 2026 06:52 GMT
New Delhi: The impending patent expiry of semaglutide drugs across … , Dr. Reddy's, Alkem, Biocon and OneSource Specialty Pharma are …
-
Generic Semaglutide patent expiry opens over Rs 50,000 Crore opportunity for drugmakers: Report
03 Jan 2026 15:29 GMT
… ], January 3 (ANI): The impending patent expiry of semaglutide drugs across … , Dr. Reddy's, Alkem, Biocon and OneSource Specialty Pharma are …
-
Ajanta Pharma signs pact with Biocon for Semaglutide
23 Dec 2025 20:07 GMT
… an in-licensing agreement with Biocon for Semaglutide.
Under the … agreement, Biocon will supply Semaglutide to Ajanta … Ajanta Pharma and Biocon said the product patent expires in most … are excited to partner with Biocon for Semaglutide and take …
-
Ajanta signs in-licensing agreement with Biocon for marketing Semaglutide in 26 countries
23 Dec 2025 19:44 GMT
… an in-licensing agreement with Biocon Ltd. for Semaglutide, a … agonist.
Under the agreement, Biocon will supply Semaglutide to Ajanta … in adults. The product patent expires in most of these … Executive Officer and Managing Director, Biocon Ltd., said, "This …
-
Ajanta Pharma to sell Biocon’s semaglutide in 26 markets
23 Dec 2025 15:07 GMT
… an in-licensing agreement with Biocon for semaglutide, the active … drugs Wegovy and Ozempic.
Biocon will supply semaglutide to … agonist, once its off-patent.
Ajanta has a branded … years ahead”. Siddharth Mittal, Biocon Chief Executive Officer and Managing …
-
Ajanta Pharma targets emerging markets for weight loss drug with Biocon tie-up
23 Dec 2025 12:02 GMT
… , has inked an agreement with Biocon to distribute generic semaglutide in … and Africa next year, as patents expire. Under the deal, Ajanta … —the semaglutide injectable pen—from Biocon and distribute it under its …
-
Biocon banks on weight-loss drugs, raises stake in biosimilar arm
12 Nov 2025 17:51 GMT
… is set to go off-patent next year.
“Filing will … once the patent expires.
However, Mittal believes Biocon’s existing … impetus".
Biosimilar growth
Biocon's biosimilars business, … successful new product launches. Biocon Biologics has introduced four …
About
© 1995-2026